EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSEEEG00000005733
Gene Symbol: NR3C1
4 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSEEEG00000015582
Gene Symbol: NR3C1
4 Cross references
207 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSEEEG00000014018
Gene Symbol: NR3C2
2 Cross references
211 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSEEEG00000023185
Gene Symbol: NOD2
4 Cross references
167 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSEEEG00000014031
Gene Symbol: OPRL1
4 Cross references
191 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSEEEG00000014100
Gene Symbol: OPRD1
4 Cross references
187 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSEEEG00000006763
Gene Symbol: OPRD1B
4 Cross references
138 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSEEEG00000009011
Gene Symbol: OPRK1
4 Cross references
200 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSEEEG00000003922
Gene Symbol: OPRM1
4 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSEEEG00000022762
Gene Symbol: OPRL1
2 Cross references
132 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSEEEG00000024457
Gene Symbol: OXTRA
4 Cross references
193 Possible Orthologues:

Oxytocin Receptor B

Ensembl ID : ENSEEEG00000021067
Gene Symbol: OXTRB
4 Cross references
136 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).